

Nicholas Wald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7983536/publications.pdf>

Version: 2024-02-01

164
papers

7,515
citations

81900

39
h-index

58581

82
g-index

172
all docs

172
docs citations

172
times ranked

8138
citing authors

#	ARTICLE	IF	CITATIONS
1	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet</i> , The, 2016, 388, 2532-2561.	13.7	1,399
2	First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. <i>New England Journal of Medicine</i> , 2005, 353, 2001-2011.	27.0	1,044
3	Antenatal Screening for Down's Syndrome. <i>Journal of Medical Screening</i> , 1997, 4, 181-246.	2.3	370
4	Childâ€“Parent Familial Hypercholesterolemia Screening in Primary Care. <i>New England Journal of Medicine</i> , 2016, 375, 1628-1637.	27.0	250
5	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-146.	2.8	204
6	PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN-A AS A SERUM MARKER. , 1996, 16, 143-153.		199
7	Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1225.	7.4	179
8	Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. <i>BMJ: British Medical Journal</i> , 2006, 333, 1114-1117.	2.3	178
9	Randomized Trial of Folic Acid Supplementation and Serum Homocysteine Levels. <i>Archives of Internal Medicine</i> , 2001, 161, 695.	3.8	166
10	Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. <i>Prenatal Diagnosis</i> , 1995, 15, 713-723.	2.3	149
11	Folic Acid and the Prevention of Neural-Tube Defects. <i>New England Journal of Medicine</i> , 2004, 350, 101-103.	27.0	146
12	Antenatal screening for Down's syndrome with the quadruple test. <i>Lancet</i> , The, 2003, 361, 835-836.	13.7	130
13	Randomized Polypill Crossover Trial in People Aged 50 and Over. <i>PLoS ONE</i> , 2012, 7, e41297.	2.5	128
14	UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. <i>BMJ: British Medical Journal</i> , 1995, 311, 1189-1193.	2.3	128
15	Cigarette consumption and serum cotinine in relation to birthweight. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1987, 94, 678-681.	2.3	117
16	The illusion of polygenic disease risk prediction. <i>Genetics in Medicine</i> , 2019, 21, 1705-1707.	2.4	110
17	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1991, 98, 905-908.	2.3	98
18	Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age. <i>PLoS ONE</i> , 2011, 6, e18742.	2.5	95

#	ARTICLE	IF	CITATIONS
19	Randomised Trial of Text Messaging on Adherence to Cardiovascular Preventive Treatment (INTERACT) Tj ETQq1 1 0.784314 ggBT /Over	2.5	84
20	Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women. PLoS ONE, 2014, 9, e89354.	2.5	82
21	Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Regional Health - Europe, The, 2021, 10, 100179.	5.6	82
22	Neural-tube defects and vitamins: the need for a randomized clinical trial. BJOG: an International Journal of Obstetrics and Gynaecology, 1984, 91, 516-523.	2.3	81
23	Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenatal Diagnosis, 2003, 23, 588-592.	2.3	79
24	Reporting the assessment of screening and diagnostic tests. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 389-396.	2.3	68
25	Headaches and the Treatment of Blood Pressure. Circulation, 2005, 112, 2301-2306.	1.6	68
26	Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate. Public Health Reviews, 2018, 39, 2.	3.2	68
27	Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts. BMJ: British Medical Journal, 1995, 311, 1530-1533.	2.3	65
28	Cotinine-assisted intervention in pregnancy to reduce smoking and low birthweight delivery. BJOG: an International Journal of Obstetrics and Gynaecology, 1991, 98, 859-865.	2.3	64
29	A case-control study of dietary carotene in men with lung cancer and in men with other epithelial cancers. Nutrition and Cancer, 1991, 15, 63-68.	2.0	63
30	Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ: British Medical Journal, 1995, 311, 1340-1343.	2.3	63
31	The use of free beta-hCG in antenatal screening for Down's syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 550-557.	2.3	60
32	Folic Acid and the Prevention of Neural Tube Defects. Annals of the New York Academy of Sciences, 1993, 678, 112-129.	3.8	60
33	Sequential and contingent prenatal screening for Down syndrome. Prenatal Diagnosis, 2006, 26, 769-777.	2.3	59
34	Grapefruit Juice and Statins. American Journal of Medicine, 2016, 129, 26-29.	1.5	57
35	Thyroid stimulating hormone and free thyroxine in pregnancy: Expressing concentrations as multiples of the median (MoMs). Clinica Chimica Acta, 2014, 430, 33-37.	1.1	55
36	The efficacy of combining several risk factors as a screening test. Journal of Medical Screening, 2005, 12, 197-201.	2.3	49

#	ARTICLE	IF	CITATIONS
37	The distribution of nuchal translucency at 10–13 weeks of pregnancy. , 1998, 18, 281-286.		48
38	Nuchal translucency and gestational age. Prenatal Diagnosis, 2004, 24, 150-151.	2.3	48
39	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 51-53.	2.3	44
40	Teleoanalysis: combining data from different types of study. BMJ: British Medical Journal, 2003, 327, 616-618.	2.3	43
41	Neural tube defects and serum zinc. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 746-749.	2.3	42
42	Assessing Risk Factors as Potential Screening Tests. Archives of Internal Medicine, 2011, 171, 286.	3.8	40
43	Screening in early pregnancy for pre-eclampsia using down syndrome quadruple test markers. Prenatal Diagnosis, 2006, 26, 559-564.	2.3	38
44	Should folic acid fortification be mandatory? Yes. BMJ: British Medical Journal, 2007, 334, 1252-1252.	2.3	30
45	Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. Prenatal Diagnosis, 2008, 28, 1094-1104.	2.3	29
46	Prenatal screening for Down syndrome and neural tube defects in twin pregnancies. Prenatal Diagnosis, 2005, 25, 740-745.	2.3	28
47	AFP and age screening for down syndrome. American Journal of Medical Genetics Part A, 1988, 31, 197-209.	2.4	27
48	Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's Syndrome. PLoS ONE, 2013, 8, e58732.	2.5	27
49	Prenatal reflex DNA screening for trisomies 21, 18, and 13. Genetics in Medicine, 2018, 20, 825-830.	2.4	24
50	Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies?. Circulation, 2017, 135, 1985-1987.	1.6	23
51	Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. European Journal of Epidemiology, 2016, 31, 415-426.	5.7	22
52	Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenatal Diagnosis, 2004, 24, 389-392.	2.3	21
53	Tests using multiple markers. , 2000, , 23-58.		21
54	Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenatal Diagnosis, 2006, 26, 514-523.	2.3	20

#	ARTICLE	IF	CITATIONS
55	Prenatal screening for open neural tube defects and Down syndrome: three decades of progress. <i>Prenatal Diagnosis</i> , 2010, 30, 619-621.	2.3	20
56	Risk Estimation Versus Screening Performance: A Comparison of Six Risk Algorithms for Cardiovascular Disease. <i>Journal of Medical Screening</i> , 2012, 19, 201-205.	2.3	20
57	Improvements in antenatal screening for Down's syndrome. <i>Journal of Medical Screening</i> , 2013, 20, 7-14.	2.3	20
58	First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free β^2 human chorionic gonadotrophin, pregnancy-associated plasma protein-A and nuchal translucency. <i>Journal of Medical Screening</i> , 2008, 15, 204-206.	2.3	19
59	The Polypill in the prevention of cardiovascular disease. <i>Preventive Medicine</i> , 2011, 52, 16-17.	3.4	19
60	Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. <i>Journal of Medical Screening</i> , 2013, 20, 57-65.	2.3	19
61	Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. <i>European Journal of Epidemiology</i> , 2014, 29, 605-612.	5.7	19
62	Integration of childâ€‘parent screening and cascade testing for familial hypercholesterolaemia. <i>Journal of Medical Screening</i> , 2019, 26, 71-75.	2.3	19
63	Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. <i>Prenatal Diagnosis</i> , 1993, 13, 1047-1050.	2.3	18
64	First Trimester Biochemical Screening for Down's Syndrome. <i>Annals of Medicine</i> , 1994, 26, 23-29.	3.8	16
65	Further observations in connection with couple screening for cystic fibrosis. <i>Prenatal Diagnosis</i> , 1995, 15, 589-590.	2.3	16
66	Routine Ultrasound Scanning for Congenital Abnormalities. <i>Annals of the New York Academy of Sciences</i> , 1998, 847, 173-180.	3.8	16
67	Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. <i>Genetics in Medicine</i> , 1999, 1, 129-135.	2.4	15
68	PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBINâ€‘A AS A SERUM MARKER. <i>Prenatal Diagnosis</i> , 1996, 16, 143-153.	2.3	14
69	Effect on down syndrome screening performance of adjusting for marker levels in a previous pregnancy. <i>Prenatal Diagnosis</i> , 2006, 26, 539-544.	2.3	13
70	Antenatal screening for Down's syndrome using the Integrated test at two London hospitals. <i>Journal of Medical Screening</i> , 2009, 16, 7-10.	2.3	13
71	The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. <i>Journal of Medical Screening</i> , 2012, 19, 51-54.	2.3	13
72	Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests. <i>PLoS ONE</i> , 2012, 7, e46955.	2.5	13

#	ARTICLE	IF	CITATIONS
73	Occupational Exposure to Hydrazine and Subsequent Risk of Lung Cancer: 50-Year Follow-Up. PLoS ONE, 2015, 10, e0138884.	2.5	13
74	Use of unconjugated oestriol in screening for Down's syndrome. Prenatal Diagnosis, 1993, 13, 1149-1153.	2.3	12
75	Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenatal Diagnosis, 2001, 21, 58-61.	2.3	12
76	Performance of antenatal reflex DNA screening for Down's syndrome. Journal of Medical Screening, 2015, 22, 168-174.	2.3	12
77	Folic acid and neural tube defects: Discovery, debate and the need for policy change. Journal of Medical Screening, 2022, 29, 138-146.	2.3	12
78	The polypill in the primary prevention of cardiovascular disease. Fundamental and Clinical Pharmacology, 2010, 24, 29-35.	1.9	11
79	Community Corner: Opening the Pandora's box of prenatal genetic testing. Nature Medicine, 2011, 17, 250-251.	30.7	11
80	Value of maternal serum unconjugated oestriol measurement in prenatal screening for Down's syndrome. Prenatal Diagnosis, 1994, 14, 699-706.	2.3	10
81	Nuchal translucency and trisomy 18. , 1999, 19, 995-996.		10
82	Body weight reduction to avoid the excess risk of type 2 diabetes. British Journal of General Practice, 2012, 62, e411-e414.	1.4	10
83	Presentation of meta-analysis plots. Journal of Medical Screening, 2015, 22, 49-51.	2.3	10
84	First-trimester amniotic fluid and extraembryonic coelomic fluid acetylcholinesterase electrophoresis. Prenatal Diagnosis, 1992, 12, 609-612.	2.3	9
85	Reflex antenatal DNA screening for Down syndrome. Prenatal Diagnosis, 2015, 35, 1154-1154.	2.3	9
86	Correlations between nuchal translucency and serum markers in SURUSS. Prenatal Diagnosis, 2004, 24, 835-836.	2.3	8
87	Discounting the Value of Life. Journal of Medical Screening, 2011, 18, 1-1.	2.3	8
88	Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. Journal of Evaluation in Clinical Practice, 2012, 18, 612-615.	1.8	8
89	Urgent need for folic acid fortification of flour and grains: response to the 2019 UK Government's public consultation. Archives of Disease in Childhood, 2020, 105, 6-9.	1.9	8
90	Validation plots in antenatal screening for Down's syndrome. Journal of Medical Screening, 2006, 13, 166-171.	2.3	7

#	ARTICLE	IF	CITATIONS
91	Specifying a Gold Standard for the Validation of Fetal Fraction Estimation in Prenatal Screening. <i>Clinical Chemistry</i> , 2018, 64, 1394-1399.	3.2	7
92	Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers. <i>Journal of Medical Screening</i> , 2012, 19, 60-67.	2.3	6
93	Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2012, 32, 299-301.	2.3	6
94	Inhibin A concentrations between 14 and 22 weeks of gestation. <i>Prenatal Diagnosis</i> , 2008, 28, 360-361.	2.3	5
95	Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in Down's syndrome screening. <i>Journal of Medical Screening</i> , 2012, 19, 49-50.	2.3	5
96	Starting the polypill: the use of a single age cut-off in males and females. <i>Journal of Medical Screening</i> , 2017, 24, 50-53.	2.3	5
97	Reply to Mulvey and Wallace. <i>Prenatal Diagnosis</i> , 2002, 22, 633-634.	2.3	4
98	Allowing for ethnic group in antenatal screening for Down's syndrome. <i>Journal of Medical Screening</i> , 2013, 20, 52-54.	2.3	4
99	The estimation of median nuchal translucency values between 10 and 14 weeks of pregnancy. <i>Journal of Medical Screening</i> , 2014, 21, 110-112.	2.3	4
100	The area under the ROC curve: Is it a valid measure of screening performance?. <i>Journal of Medical Screening</i> , 2014, 21, 220-220.	2.3	4
101	The Triple Test. <i>Clinical Chemistry</i> , 2014, 60, 269-270.	3.2	4
102	Insulin dependent diabetes mellitus (IDDM) and first trimester markers in prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2016, 36, 192-193.	2.3	4
103	Prenatal reflex DNA screening for Down syndrome: enhancing the screening performance of the initial first trimester test. <i>Prenatal Diagnosis</i> , 2016, 36, 328-331.	2.3	4
104	Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies. <i>Prenatal Diagnosis</i> , 2018, 38, 1079-1085.	2.3	4
105	The distribution of nuchal translucency at 10-13 weeks of pregnancy. <i>Prenatal Diagnosis</i> , 1998, 18, 281-286.	2.3	4
106	Medical screening. , 2010, , 94-108.		4
107	Response to Walker. <i>Genetics in Medicine</i> , 2018, 20, 1295-1295.	2.4	4
108	Mandatory UK folic acid fortification. <i>Lancet</i> , The, 2021, 398, 1961-1962.	13.7	4

#	ARTICLE	IF	CITATIONS
109	Down syndrome fetal loss rate in early pregnancy. <i>Prenatal Diagnosis</i> , 2000, 20, 685-686.	2.3	3
110	Cost-effectiveness of diagnosis of high blood pressure in primary care. <i>Lancet, The</i> , 2012, 379, 709-710.	13.7	3
111	Personalized medicine: hope or hype. <i>European Heart Journal</i> , 2012, 33, 1553-1554.	2.2	3
112	Antenatal screening for Downâ€™s syndrome, trisomy 18, and trisomy 13: Reporting a single screening result for all three. <i>Journal of Medical Screening</i> , 2015, 22, 100-105.	2.3	3
113	Randomized Crossover Trial of Phosphate-binding Medication on Serum Phosphate Levels in Patients With Aortic Stenosis. <i>Clinical Therapeutics</i> , 2019, 41, 2066-2072.e2.	2.5	3
114	Two under-recognized limitations of number needed to treat. <i>International Journal of Epidemiology</i> , 2020, 49, 359-360.	1.9	3
115	Medical screening. , 2010, , 95-108.		3
116	Inhibin-A regression. , 1999, 19, 893-894.		2
117	Reply to Professor Hook. <i>Prenatal Diagnosis</i> , 2004, 24, 1018-1018.	2.3	2
118	Refining the American guidelines for prevention of cardiovascular disease. <i>Lancet, The</i> , 2014, 383, 598.	13.7	2
119	Sodium and cardiovascular disease. <i>Lancet, The</i> , 2016, 388, 2111-2112.	13.7	2
120	Discounting financial costs and health benefits in public health programmes. <i>Journal of Medical Screening</i> , 2016, 23, 115-115.	2.3	2
121	Antenatal reflex DNA screening for trisomy 18 and trisomy 13 in addition to Downâ€™s syndrome. <i>Journal of Medical Screening</i> , 2016, 23, 171-174.	2.3	2
122	The NHS Health Checks programme: A better alternative. <i>Journal of Medical Screening</i> , 2016, 23, 57-58.	2.3	2
123	Sharing Clinical Trial Data. <i>Journal of Medical Screening</i> , 2017, 24, 57-57.	2.3	2
124	Screening and preventive medication. <i>Journal of Medical Screening</i> , 2017, 24, 169-169.	2.3	2
125	Prenatal reflex DNA screening for trisomy 21, 18 and 13. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 399-401.	3.1	2
126	Serum marker truncation limits in first trimester antenatal screening for trisomy 18. <i>Journal of Medical Screening</i> , 2018, 25, 169-173.	2.3	2

#	ARTICLE	IF	CITATIONS
127	Nuchal translucency and trisomy 18. <i>Prenatal Diagnosis</i> , 1999, 19, 995-996.	2.3	2
128	Prenatal maternal plasma DNA screening for cystic fibrosis: A computer modelling study of screening performance. <i>F1000Research</i> , 2017, 6, 1896.	1.6	2
129	Down's syndrome screening: Value of using free β -hCG. <i>Prenatal Diagnosis</i> , 1995, 15, 94-95.	2.3	1
130	Response to Nicolaides. <i>Prenatal Diagnosis</i> , 2004, 24, 834-835.	2.3	1
131	In response to Nicolaides. <i>Prenatal Diagnosis</i> , 2004, 24, 317-318.	2.3	1
132	Recurrent false-positives in AFP screening for open neural tube defects. <i>Prenatal Diagnosis</i> , 2004, 24, 1018-1019.	2.3	1
133	Cross trimester marker ratios: parameter estimates valid with no inconsistency. <i>Prenatal Diagnosis</i> , 2006, 26, 994-994.	2.3	1
134	Truncation limits for CT marker ratios in prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2007, 27, 187-188.	2.3	1
135	Contingent screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2008, 28, 781-781.	2.3	1
136	Unified prenatal screening for Down's syndrome and pre-eclampsia. <i>Clinical Biochemistry</i> , 2011, 44, 455.	1.9	1
137	Screening for cardiovascular disease: Concerns with a Norwegian proposal. <i>Journal of Medical Screening</i> , 2011, 18, 165-166.	2.3	1
138	Effect of interrupting prenatal Down syndrome screening due to a large nuchal translucency. <i>Prenatal Diagnosis</i> , 2012, 32, 655-661.	2.3	1
139	When Guidelines Cause Hypertension. <i>American Journal of Medicine</i> , 2018, 131, 1402-1404.	1.5	1
140	Conflating screening detection rates with the uptake of further testing: A potential source of confusion. <i>Journal of Medical Screening</i> , 2019, 26, 1-2.	2.3	1
141	Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13. <i>PLoS ONE</i> , 2019, 14, e0220053.	2.5	1
142	Antenatal screening for Down's syndrome: Revised nuchal translucency upper truncation limit due to improved precision of measurement. <i>Journal of Medical Screening</i> , 2021, 28, 88-92.	2.3	1
143	Efficacy and effectiveness. <i>Journal of Medical Screening</i> , 2021, 28, 57-58.	2.3	1
144	A limitation of genetic epidemiological analysis when associations are genuinely J-shaped illustrated using a prospective study of alcohol consumption and vascular disease. <i>International Journal of Epidemiology</i> , 2022, 50, 1757-1760.	1.9	1

#	ARTICLE	IF	CITATIONS
145	Risk or chance. Journal of Medical Screening, 2022, , 096914132110682.	2.3	1
146	Blood pressure meta-analysis highlights an implementation gap. Lancet, The, 2022, 399, 1379-1380.	13.7	1
147	Paying for publication. Journal of Medical Screening, 2007, 14, 1-1.	2.3	0
148	The Canadian Recommendations on Screening for Type 2 Diabetes. Journal of Medical Screening, 2012, 19, 163-163.	2.3	0
149	Reply. European Thyroid Journal, 2012, 1, 134-134.	2.4	0
150	The press, press releases, and raising unwarranted expectations. Journal of Medical Screening, 2013, 20, 55-56.	2.3	0
151	Cochrane report on lowering blood pressure. Journal of Medical Screening, 2014, 21, 3-4.	2.3	0
152	The Reply. American Journal of Medicine, 2016, 129, e303.	1.5	0
153	The Limited Public Health Impact of "Lifestyle" Change. American Journal of Medicine, 2016, 129, 1236.	1.5	0
154	Antenatal reflex DNA screening for Down's syndrome using total instead of free B-hCG in the Combined test. Journal of Medical Screening, 2016, 23, 50-51.	2.3	0
155	Sequential integrated antenatal screening for Down's syndrome, trisomy 18 and trisomy 13. Journal of Medical Screening, 2016, 23, 116-123.	2.3	0
156	Blood pressure and cardiovascular outcomes: a closer look. Lancet, The, 2017, 389, 1296.	13.7	0
157	The Need to Interpret the Results of a Clinical Trial in the Context of Other Evidence. American Journal of Medicine, 2017, 130, 251-252.	1.5	0
158	Medical Screening Society members' talks. Journal of Medical Screening, 2018, 25, 113-113.	2.3	0
159	A simple method to allow for guanine-cytosine amplification error in prenatal DNA screening for trisomy 18. Clinica Chimica Acta, 2019, 496, 13-17.	1.1	0
160	Are screening practice ethics committees needed?. Journal of Medical Screening, 2021, 28, 096914132110392.	2.3	0
161	Multi-marker risk-based screening for prostate cancer. Journal of Medical Screening, 2022, , 096914132210764.	2.3	0
162	"Risk or chance": Authors' response. Journal of Medical Screening, 2022, , 096914132210898.	2.3	0

#	ARTICLE	IF	CITATIONS
163	When primary prevention replaces screening. Journal of Medical Screening, 2021, , 096914132110659.	2.3	0
164	When alternatives to screening should be the priority. Journal of Medical Screening, 0, , 096914132211023.	2.3	0